GSK Statistics
Total Valuation
GSK has a market cap or net worth of $79.09 billion. The enterprise value is $97.20 billion.
Important Dates
The next confirmed earnings date is Wednesday, July 30, 2025, before market open.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | May 16, 2025 |
Share Statistics
GSK has 4.08 billion shares outstanding. The number of shares has increased by 0.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.08B |
| Shares Change (YoY) | +0.73% |
| Shares Change (QoQ) | -0.19% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.91B |
Valuation Ratios
The trailing PE ratio is 19.41 and the forward PE ratio is 8.28.
| PE Ratio | 19.41 |
| Forward PE | 8.28 |
| PS Ratio | 1.94 |
| Forward PS | 3.17 |
| PB Ratio | 4.48 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.71 |
| P/OCF Ratio | 9.08 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.69, with an EV/FCF ratio of 13.16.
| EV / Earnings | 23.86 |
| EV / Sales | 2.39 |
| EV / EBITDA | 8.69 |
| EV / EBIT | 12.03 |
| EV / FCF | 13.16 |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 1.35.
| Current Ratio | 0.87 |
| Quick Ratio | 0.58 |
| Debt / Equity | 1.35 |
| Debt / EBITDA | 2.08 |
| Debt / FCF | 3.22 |
| Interest Coverage | 10.32 |
Financial Efficiency
Return on equity (ROE) is 27.10% and return on invested capital (ROIC) is 12.39%.
| Return on Equity (ROE) | 27.10% |
| Return on Assets (ROA) | 6.55% |
| Return on Invested Capital (ROIC) | 12.39% |
| Return on Capital Employed (ROCE) | 15.68% |
| Revenue Per Employee | $593,563 |
| Profits Per Employee | $59,358 |
| Employee Count | 68,629 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.51 |
Taxes
In the past 12 months, GSK has paid $759.70 million in taxes.
| Income Tax | 759.70M |
| Effective Tax Rate | 13.90% |
Stock Price Statistics
The stock price has decreased by -0.75% in the last 52 weeks. The beta is 0.27, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -0.75% |
| 50-Day Moving Average | 38.74 |
| 200-Day Moving Average | 37.31 |
| Relative Strength Index (RSI) | 44.64 |
| Average Volume (20 Days) | 5,060,649 |
Short Selling Information
| Short Interest | 16.48M |
| Short Previous Month | 16.76M |
| Short % of Shares Out | 0.81% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.41 |
Income Statement
In the last 12 months, GSK had revenue of $40.74 billion and earned $4.07 billion in profits. Earnings per share was $0.98.
| Revenue | 40.74B |
| Gross Profit | 29.30B |
| Operating Income | 8.08B |
| Pretax Income | 6.06B |
| Net Income | 4.07B |
| EBITDA | 11.18B |
| EBIT | 8.08B |
| Earnings Per Share (EPS) | $0.98 |
Full Income StatementBalance Sheet
The company has $5.79 billion in cash and $23.81 billion in debt, giving a net cash position of -$18.02 billion or -$4.41 per share.
| Cash & Cash Equivalents | 5.79B |
| Total Debt | 23.81B |
| Net Cash | -18.02B |
| Net Cash Per Share | -$4.41 |
| Equity (Book Value) | 17.64B |
| Book Value Per Share | 4.48 |
| Working Capital | -3.55B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $8.71 billion and capital expenditures -$1.76 billion, giving a free cash flow of $7.38 billion.
| Operating Cash Flow | 8.71B |
| Capital Expenditures | -1.76B |
| Free Cash Flow | 7.38B |
| FCF Per Share | $1.81 |
Full Cash Flow StatementMargins
Gross margin is 71.92%, with operating and profit margins of 19.83% and 10.00%.
| Gross Margin | 71.92% |
| Operating Margin | 19.83% |
| Pretax Margin | 13.42% |
| Profit Margin | 10.00% |
| EBITDA Margin | 27.45% |
| EBIT Margin | 19.83% |
| FCF Margin | 18.13% |
Dividends & Yields
This stock pays an annual dividend of $1.58, which amounts to a dividend yield of 4.09%.
| Dividend Per Share | $1.58 |
| Dividend Yield | 4.09% |
| Dividend Growth (YoY) | 8.04% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 160.28% |
| Buyback Yield | -0.73% |
| Shareholder Yield | 3.36% |
| Earnings Yield | 5.15% |
| FCF Yield | 9.34% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 4.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 0.8:1.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.8:1 |
Scores
GSK has an Altman Z-Score of 1.78 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.78 |
| Piotroski F-Score | 6 |